Works matching AU Seidel, Diana

Results: 11

Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment.

Published in:

Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-018-37188-0

By:

Erdmann, Sarah;
Seidel, Diana;
Jahnke, Heinz-Georg;
Eichler, Marie;
Simon, Jan-Christoph;
Robitzki, Andrea A.

Publication type:

Article

Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice.

Published in:

Cancer Immunology, Immunotherapy, 2015, v. 64, n. 10, p. 1215, doi. 10.1007/s00262-015-1733-1

By:

Stermann, Alexander;
Huebener, Nicole;
Seidel, Diana;
Fest, Stefan;
Eschenburg, Georg;
Stauder, Michael;
Schramm, Alexander;
Eggert, Angelika;
Lode, Holger

Publication type:

Article

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.

Published in:

Cancer Immunology, Immunotherapy, 2015, v. 64, n. 5, p. 621, doi. 10.1007/s00262-015-1669-5

By:

Seidel, Diana;
Shibina, Anastasia;
Siebert, Nikolai;
Wels, Winfried;
Reynolds, C.;
Huebener, Nicole;
Lode, Holger

Publication type:

Article

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD-specific anti-neuroblastoma immune response.

Published in:

Cancer Immunology, Immunotherapy, 2013, v. 62, n. 6, p. 999, doi. 10.1007/s00262-013-1413-y

By:

Lode, Holger;
Schmidt, Manuela;
Seidel, Diana;
Huebener, Nicole;
Brackrock, Diana;
Bleeke, Matthias;
Reker, Daniel;
Brandt, Sven;
Mueller, Hans-Peter;
Helm, Christiane;
Siebert, Nikolai

Publication type:

Article

Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody.

Published in:

PLoS ONE, 2014, v. 9, n. 9, p. 1, doi. 10.1371/journal.pone.0107692

By:

Siebert, Nikolai;
Seidel, Diana;
Eger, Christin;
Jüttner, Madlen;
Lode, Holger N.

Publication type:

Article

A Novel 3D Label-Free Monitoring System of hES-Derived Cardiomyocyte Clusters: A Step Forward to In Vitro Cardiotoxicity Testing.

Published in:

PLoS ONE, 2013, v. 8, n. 7, p. 1, doi. 10.1371/journal.pone.0068971

By:

Jahnke, Heinz-Georg;
Steel, Daniella;
Fleischer, Stephan;
Seidel, Diana;
Kurz, Randy;
Vinz, Silvia;
Dahlenborg, Kerstin;
Sartipy, Peter;
Robitzki, Andrea A.

Publication type:

Article

Induced Tauopathy in a Novel 3D-Culture Model Mediates Neurodegenerative Processes: A Real-Time Study on Biochips.

Published in:

PLoS ONE, 2012, v. 7, n. 11, p. 1, doi. 10.1371/journal.pone.0049150

By:

Seidel, Diana;
Krinke, Dana;
Jahnke, Heinz-Georg;
Hirche, Anika;
Kloß, Daniel;
Mack, Till G. A.;
Striggow, Frank;
Robitzki, Andrea

Publication type:

Article

Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.

Published in:

mAbs (1942-0862), 2016, v. 8, n. 3, p. 604, doi. 10.1080/19420862.2015.1130196

By:

Siebert, Nikolai;
Eger, Christin;
Seidel, Diana;
Jüttner, Madlen;
Zumpe, Maxi;
Wegner, Danilo;
Kietz, Silke;
Ehlert, Karoline;
Veal, Gareth J.;
Siegmund, Werner;
Weiss, Michael;
Loibner, Hans;
Ladenstein, Ruth;
Lode, Holger N.

Publication type:

Article

NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

Published in:

Journal of Cellular & Molecular Medicine, 2012, v. 16, n. 3, p. 569, doi. 10.1111/j.1582-4934.2011.01343.x

By:

Esser, Ruth;
Müller, Tina;
Stefes, Dörthe;
Kloess, Stephan;
Seidel, Diana;
Gillies, Stephen D.;
Aperlo-Iffland, Christel;
Huston, James S.;
Uherek, Christoph;
Schönfeld, Kurt;
Tonn, Torsten;
Huebener, Nicole;
Lode, Holger N.;
Koehl, Ulrike;
Wels, Winfried S.

Publication type:

Article

Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.

Published in:

PLoS ONE, 2016, v. 11, n. 3, p. 1, doi. 10.1371/journal.pone.0150479

By:

Eger, Christin;
Siebert, Nikolai;
Seidel, Diana;
Zumpe, Maxi;
Jüttner, Madlen;
Brandt, Sven;
Müller, Hans-Peter;
Lode, Holger N.

Publication type:

Article

Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.

Published in:

Journal of Molecular Medicine, 2013, v. 91, n. 4, p. 459, doi. 10.1007/s00109-012-0958-0

By:

Shibina, Anastasia;
Seidel, Diana;
Somanchi, Srinivas;
Lee, Dean;
Stermann, Alexander;
Maurer, Barry;
Lode, Holger;
Reynolds, C.;
Huebener, Nicole

Publication type:

Article

Works matching AU Seidel, Diana

Induced cross-resistance of BRAF<sup>V600E</sup> melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment.

Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice.

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD-specific anti-neuroblastoma immune response.

Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD<sub>2</sub> Antibody.

A Novel 3D Label-Free Monitoring System of hES-Derived Cardiomyocyte Clusters: A Step Forward to <i>In Vitro</i> Cardiotoxicity Testing.

Induced Tauopathy in a Novel 3D-Culture Model Mediates Neurodegenerative Processes: A Real-Time Study on Biochips.

Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.

NK cells engineered to express a GD<sub>2</sub>-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

Generation and Characterization of a Human/Mouse Chimeric GD<sub>2</sub>-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.

Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.